The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis. Two single nucleotide polymorphisms in the IL-1RA gene (rs4251961 T/C and rs579543 C/T) influence IL-1RA circulating levels with highest production in carriers of the homozygous rs4251961 T/T and rs579543 T/T genotypes. A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers). Median survival times were 35.8 months (95% confidence interval: 29.7-43.7 months) and 28.6 months (95% confidence interval: 25.6-30 months) in 56 T/T carriers and in 124 non-T/T carriers, respectively. The favorable association between T/T carriers' status and survival was significant in the multivariate analysis (P ¼ 0.018). Also, T/T carriers and non-T/T carriers were prevalent among patients with Karnofsky performance status 90-100 and 70-80, respectively (P ¼ 0.002). These findings encourage additional studies in this field and the evaluation of a recombinant-IL-1RA for anticancer activity.
Introduction
The interleukin-1 receptor antagonist (IL-1RA) cytokine is present in the circulation of healthy individuals. Extensive evidence indicates that the biological function of secreted IL-1RA is to competitively inhibit the binding of circulating IL-1b to cell-surface receptors. 1 In vivo, the potentially injurious proinflammatory effects of IL-1b are counterbalanced by the action of the IL-1RA, whose levels increase late during the course of an inflammatory event to terminate acute inflammation. 1 In recent years, the roles of the IL-1b and its counterpart IL-1RA have been studied in cancer. 2 In cancer patients, IL-1b has been found to be involved in the molecular mechanisms of the anorexia/cachexia syndrome 3 and it is considered a mediator of tumor angiogenesis and metastasis, [4] [5] [6] [7] [8] whereas IL-1RA antagonizes the tumor-promoting effects of IL-1b both in vitro and in vivo. 2 Evidence indicates interindividual differences in the circulating levels of IL-1RA. 9 These differences are thought to be due to functional genetic variants in the IL-1RA gene (IL-1RA) [10] [11] [12] [13] [14] [15] located on chromosome 2q14. Rafiq et al. 15 demonstrated that two IL-1RA single nucleotide polymorphisms (SNPs) were strongly associated with different IL-1RA levels in vivo. In the inCHIANTI study, seven SNPs that capture a large proportion of common genetic variants in the IL-1RA gene were studied in 1256 Caucasian healthy individuals in Central Italy. The homozygous rs4251961 T/T genotype (T/C variant) and the homozygous rs579543 T/T genotype (C/T variant) showed the strongest association with high IL-1RA levels. 15 Notably, the rs579543 C/T polymorphism tags a known variable number tandem repeats (VNTR) polymorphism in intron 2, which was previously found to influence IL-1RA levels in vivo. The VNTR2* allele of this variant is associated with increased IL-1RA levels and in a previous study, we have found that VNTR2* was a favorable genetic status for prognosis of patients with metastatic gastric cancer. 16 This background prompted us to initiate a new study to determine whether IL-1RA genotypes associated with high IL-1RA circulating levels are also associated with favorable survival of patients with advanced colorectal cancer. This information may simply not be an additional prognostic features, but may support further investigations in this field for novel therapeutics. Such therapeutics may provide the possibility of new anticancer treatment strategies, including clinical examination of a recombinant IL-1RA presently used against inflammatory diseases. 
Results

Characteristics of patients
The genotype frequencies in all 180 patients and the resulting study groups are shown in Table 1 . No deviation from HWE was observed (w 2 -test). Table 2 summarizes the characteristics of the 180 patients, the 56 T/T carriers and the 124 non-T/T carriers. Notably, there was a higher proportion of patients with Karnofski performance status (KPS) 90-100 in the group of T/T carriers (86%) than in the group of patients without a T/T genotype (63%). Conversely, a higher proportion of non-T/T carriers (37%) had KPS 70-80 than T/T carriers (14%). This difference was statistically significant at a level of P ¼ 0.002 (w 2 -test). No additional significant associations were found between the two genotype groups and patients'characteristics.
Survival analysis
At the time of writing this report, 141 out of the 180 patients (78%) had died. In the whole group, the median survival time was 29.5 months (95% confidence interval (CI) ¼ 28.2-32.4 months). Survival plots were preliminary analyzed for each polymorphism indicating the trend for favorable survival in T/T carriers of both variants (Figures 1a and b) . Median survival times for carriers of rs4251961 C/C, C/T and T/T genotypes were 28 months, 29.6 months and 35 months, respectively (Panel a). Median survival times for carriers of rs579543 C/C, C/T and T/T genotypes were 29 months, 30.2 months and 46.7 months, respectively (Panel b).
Survival curves of T/T carriers and non-T/T carriers are shown in Panel C of Figure 1 . Median survival times were 35.8 months (95% CI ¼ 29.7-43.7 months) and 28.6 months (95% CI ¼ 25.6-30 months) for T/T carriers and non-T/T carriers, respectively. This difference was statistically significant (log-rank w 2 : 6.16, P ¼ 0.01). Additional factors, which showed association with survival in the univariate model were sex, KPS score, carcinoembryonic antigen (CEA) levels and treatment with cetuximab. The results of the multivariate analysis are shown in Table 3 . Low KPS (70-80) and elevated CEA levels were associated with poor survival, whereas treatment with cetuximab and carrying an IL-1RA T/T genotype were associated with favorable survival. 
*The global number of carriers of a T/T genotype is 65. The study group of 56 T/T carriers includes 47 carriers of at least one T/T genotype and 9 carriers of both rs4251961 T/T and rs579543 T/T genotypes. Table 2 Characteristics of the 180 patients and their distribution according to the study groups 
Analysis of LD and haplotypes
There was weak linkage disequilibrium (LD) between alleles of the IL-1RN rs4251961 and rs579543 loci with r 2 ¼ 0.17, suggesting the two variants segregate independently to a large extent. As every patient carries two IL-1RN haplotypes, we estimated haplotype constellations in individual patients using the HAP analysis tool, yielding seven patient groups differing in their two haplotypes (Table 4) . Consistent with the genotype results, haplotypes groups (4-7) resulting in at least one T allele from both variants had the longest median OS (Table 4) . Accordingly, their combination (TC/TT) showed longer median survival than the haplotype grouping that included CC carriers (Mann-Whitney test, P ¼ 0.005).
Discussion
Significant survival improvements have been achieved in patients with metastatic colorectal cancer in the last decades. The use of oxaliplatin and irinotecan in combination with 5-fluorouracil has allowed the adoption of noncross-resistant first-and second-line chemotherapy regimens with estimated survival times exceeding 20 months when all the three drugs are used in the course of the disease. 17 More recently, targeted therapies against epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor have additionally improved outcomes of these patients. Treatment strategies for patients with metastatic colorectal cancer are rapidly changing and further improvements can be expected from the optimized use of available drugs and from the discovery of novel targets and compounds with a role in the disease. The planning of the present study is to be viewed the perspective of hypothetical novel treatments for patients with metastatic colorectal cancer and extends beyond a simple determination of an additional prognostic feature. The fact that a genotype-dependent plasma level of a specific cytokine could impact on the survival of these patients may open new perspectives regarding the IL-1b/IL-1RA network as a therapeutic target. 2 Our first finding was that the IL-1RA genotype status was significantly associated with KPS. The group of T/T carriers and the group of patients without a T/T genotype were prevalent in patients with KPS 90-100 and KPS 70-80, respectively. This aspect suggests that elevated circulating levels of IL-1RA may balance the proinflammatory and procachectic effects of a negative network of cytokines, such as IL-1b, thereby maintaining a favorable performance status. Few clinical investigations have addressed this specific issue, in vivo studies have shown a deterioration of clinical parameters in patients with gastrointestinal malignancies when their circulating levels of IL-1RA were low. [18] [19] [20] The opposing effects of IL-1RA in inflammation and cachexia may contribute to the observed survival benefit associated with IL-1RA genotypes that upregulate the cytokine's circulating levels. However, experimental and in vivo studies have demonstrated that IL-1RA exerts additional antitumor and in particular, antiangiogenetic effects. [21] [22] [23] [24] [25] [26] It is a matter of debate whether the antiangiogenic effects of the cytokine are a direct result of its activity, or rather due to its function in counterbalancing the detrimental cascade of IL-1b. 8 Data from experimental models suggest that the antiangiogenic activity of IL-1RA may require IL-1b-driven tumor angiogenesis, implying that its role as a negative regulator is important in this process. 25, 26 IL-1RA variants in advanced colorectal cancer patients
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We used IL-1RA genotypes instead of IL-1RA levels for the present clinical investigation. This choice was made because convincing evidence has established an association between the studied IL-1RA variants and IL-1RA circulating levels. 15 Genotyping has the advantage of a yes/no result and can be easily performed. The adopted HMRA methodology for assessing SNPs (Figure 2 ) has additional practical advantages compared to other genotyping methods (that is, PCR-RFLP or sequencing). 27 Knowledge on the genotypes status may also be informative regarding more complex interactions within the IL-1RA/IL-1b network. In fact, Rafiq et al. 15 found that the rs4251961 C/C genotype (resulting in low IL-1RA levels) was associated with increased IL-1b production. The mechanism underlying this observation is unclear, but a possible genetic interplay may modulate the IL-1RA/IL-1b system and cause a double unfavorable effect with simultaneous lowered IL-1RA levels and increased IL-1b levels. Regarding the rs579543 variant it is not clear whether its impact on IL-1RA level is direct effect. In fact, rs579543 is in LD with a known VNTR polymorphism in IL-1RA intron 2. The VNTR variant was found to be associated with the outcome in patients with metastatic gastric cancer treated with palliative chemotherapy. 16 Furthermore, preliminary data suggest the IL-1RA VNTR may predict the likelihood of tumor recurrence in patients with surgically-resected, stage II colorectal cancer. 28 Notably, the allele 2 of the IL-1RA VNTR is rare in Asians and a similar difference could involve the linked IL-1RA rs579543 variant. Differences in genotype frequencies among ethnic groups should be considered for assessing the reproducibility of prognostic associations.
Consistent with the inCHIANTI study, 15 there was only weak LD between the rs4251961 and rs579543 loci. Therefore, and regardless whether these two variants are tagged to other polymorphisms not investigated here, their effects on patient survival appear to be convergent and largely independent from each other. It hence was appropriate to analyze the associated genotypes as an individual 'T/T' group. Stratifying patients according to their two IL-1RA haplotypes corroborated the findings of the genotype analysis; all haplotype combinations resulting in a homozygous T/T genotype were associated with improved survival (Table 4) . The genotype analysis further suggested that the contribution of the rs579543 T/T genotype to favorable outcome was larger than that of the rs4251961 T/T genotype (Figures 1a  and b) . Consistent with this possibility, the longest survival was observed in patients whose haplotypes included a homozygous T/T genotype for rs4251961 (Table 4) .
To the best of our knowledge, this is the first report that has explored the association between functional IL-1RA genotypes and the survival of patients with metastatic colorectal cancer. The finding of favorable survival in carriers of IL-1RA genotypes associated with elevated cytokine levels is likely to be linked to protective IL-1RA activity antagonizing the effects of IL-1b. It is possible that a combined analysis of the IL-1RA variants with Interleukin-1b gene polymorphisms could supply a more precise information on the interplay between the two cytokine. However, more robust data IL-1RA variants in advanced colorectal cancer patients indicating which one of the known Interleukin-1b polymorphisms upregulates the circulating level of the cytokine in vivo are needed. These results encourage additional studies in this field and the planning of clinical investigations into a commercially available recombinant IL-1RA (Anakinra) 29 in patients with colorectal cancer and also other solid tumors. A pretreatment genotyping of IL-1RA variants could further aid at identifying patients deriving maximum benefit (that Figure 2 Image showing the result of a genetic analysis using the HMR technique for assessing IL-1RA polymorphism. (a and c) Normalized plot of rs579543 and rs4251961 genotypes respectively. Fluorescence is on the y axis and temperature is on the x axis (Celsius degrees). (b and d) Difference plot of rs579543 and rs4251961 genotypes. In difference plots, the melting profile of a wild-type control is chosen as a horizontal base line and the relative differences in the melting of all the other samples are plotted relative to this baseline.
IL-1RA variants in advanced colorectal cancer patients is, low IL-1RA producers) from this potential therapeutic approach.
Materials and methods
Study population
Patients with metastatic colorectal cancer who were prospectively enrolled in two pharmacogenetic studies for first-line chemotherapy with FOLFOX 30 regimen (folinic acid, bolus/ infusional 5-fluorouracil and oxaliplatin every 14 days) or FOLFIRI 31 regimen (folinic acid, bolus/infusional 5-fluorouracil and irinotecan every 14 days) were also considered eligible for a second analysis addressing the association between survival and rs4251961 T/C and rs579543 C/T variants in IL-1RA. For the purpose of the study, patients were required to receive second-line chemotherapy including irinotecan or oxaliplatin if they had underwent FOLFOX or FOLFIRI in first-line chemotherapy, respectively. This allowed the analysis in a population of patients who were homogeneously treated with the three main active drugs in the disease. 17 Salvage therapy including cetuximab was allowed in patients with positive immunohistochemistry for EGFR expression in the tumor. Additional eligibility criteria were cytologically or histologically confirmed metastatic disease, presence of at least one bidimensionally measurable lesion, KPS X70. Pretreatment evaluation included complete medical and clinical-physical examination, KPS evaluation, assessment of metastatic disease based on CT scans, X-ray or other radiographic means, serum chemistries and CEA. Patients' characteristics and their outcomes were unknown to investigators performing genetic analyses. The study was approved by local ethical committees and patients provided signed informed consent.
Analysis of genetic variants
For each enrolled patient, a peripheral blood sample was used for DNA extraction and genotyping. Genomic DNA was extracted using the QiaAmp kit (Qiagen, Valencia, CA, USA). IL-1RA variants were determined using the high-resolution melting analysis (HRMA). 27 HRMA is a closed-tube fluorescent-based method for rapid mutation screening and detection of single-base substitutions, deletions or similarly small mutational deviations from the wild-type sequence. 27 In brief, primer sequences were designed to obtain the best HRM performance, avoiding hairpin and primer-dimer formation and maintaining the amplicon length as short as possible. The Primer3Plus software (http://www.bioinformatics. nl/cgi-bin/primer3plus/primer3plus.cgi) was used for primers design. The amplicon size for rs4251961 T/C in IL-1RA 5 0 untraslated region, was 145bp and primer sequences were forward 5 0 -ACCTGCAGCAAGGGCCTGTGTA; reverse: 7) was used for HMRA. Normalized graphs and difference graphs were used to analyze the data. All samples including wild types were plotted according to their melting profiles. In the difference graph, the melting profiles of each sample were compared to those of wild types converted to a horizontal line. Significant deviations from the horizontal line (relative to the spread of the wild-type controls) were indicative of sequence changes within the amplicon analyzed. Samples with aberrant melting curves were recorded as HRMA mutation positive. An example of an HRMA results is shown in Figure 2 . For each variant, HRMA results from ten randomly selected samples were validated by DNA sequencing.
Statistical analyses
The primary end point of the study was to investigate the association between IL-1RA variants and survival of patients with metastatic colorectal cancer. According to the biological background (highest IL-1RA circulating levels in carriers of the homozygous rs4251961 T/T genotype and/or rs579543 T/T genotype) and considering the similar functional effects of the two variants, the study population was dichotomized into two groups. The study group consisted of carriers of at least one T/T genotype (rs4251961 T/T, or rs579543 T/T, or both), whereas the control group included the remaining patients (non-T/T carriers). Before analyses, genotypes from the two studied polymorphisms were examined for deviation from Hardy-Weinberg equilibrium (HWE) by comparing actual allelic distributions with those expected from HWE.
A total of 180 patients met the inclusion criteria and they were enrolled in the study. Their survival time was calculated from the start of first-line chemotherapy to death from any cause. We assumed the presence of a favorable genetic profile (that is, the study group) in at least one-third of the enrolled patients and tested the hypothesis of favorable association with survival after a minimum of 2-year follow-up period and with events in 75% of the total sample patients. This number would allow detection of a relative hazard reduction of at least 30% (80% power and 5% type I error for a two-tailed test).
The Kaplan-Meier method was adopted to estimate survival curves and the log-rank test was used to compare the patients' survival time between genotype groups. Cox proportional hazards models as implemented in the PHREG program in SAS (SAS Institute Inc., Cary, NC, USA) were used to estimate and test the two genotype groups and clinicopathologic features (age, sex, KPS, CEA levels, number of organs involved, presence of liver metastasis) for their association with survival. Given the clinically relevant IL-1RA variants in advanced colorectal cancer patients importance of treatment with cetuximab in the course of the disease, this feature was added to the models as a dichotomous variable (treatment yes vs no). Variables that were found to be associated with survival in the univariate analysis were considered for multivariate analysis. Results are expressed as hazard ratios with 95% CIs.
Linkage disequilibrium and haplotype analyses were performed to further define possible clinical effects of genetic variants. 32 A haplotype is a combination of alleles at multiple loci (that is, two or more SNPs) that are transmitted together on the same chromosome. LD exists between two SNPs of a haplotype, if their variants appear together more often than expected (nonrandom inheritance). LD was estimated using r 2 ¼ 1 indicating complete LD and r 2 ¼ 0 absence of LD (http://analysis.bio-x.cn/ myAnalysis.php). The HAP analysis tool (http://diego.cs. ucla.edu/hap/html/) was used to assign haplotypes to individual patients. 33 Patients were stratified according to their haplotypes and their median survival values were calculated.
The w 2 -test and the Mann-Whitney test were used as appropriate. Statistical significance was set at Po0.05 and all P-values were two sided.
